Rosemary (Rosmarinus officinalis L.) extract inhibits prostate cancer cell proliferation and survival by targeting Akt and mTOR.
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Humans
Male
Plant Extracts
/ pharmacology
Prostatic Neoplasms
/ drug therapy
Proto-Oncogene Proteins c-akt
/ antagonists & inhibitors
Rosmarinus
Signal Transduction
/ drug effects
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Akt
Proliferation
Prostate cancer
Rosemary extract
Survival
mTOR
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
28
07
2020
revised:
28
08
2020
accepted:
30
08
2020
entrez:
6
11
2020
pubmed:
7
11
2020
medline:
23
2
2021
Statut:
ppublish
Résumé
Prostate cancer is the most commonly diagnosed type of cancer in North American men and is typically classified as either androgen receptor positive or negative depending on the expression of the androgen receptor (AR). AR positive prostate cancer can be treated with hormone therapy while AR negative prostate cancer is aggressive and does not respond to hormone therapy. It has been previously reported that rosemary extract (RE) has antioxidant, anti-inflammatory and anti-cancer properties. In the present study, we found that treatment of the androgen-insensitive PC-3 prostate cancer cells with RE resulted in a significant inhibition of proliferation, survival, migration, Akt, and mTOR signaling. In addition, treatment of the androgen-sensitive 22RV1 prostate cancer cells with RE resulted in a significant inhibition of proliferation and survival while RE had no effect on normal prostate epithelial PNT1A cells. These findings suggest that RE has potent effects against prostate cancer and warrants further investigation.
Identifiants
pubmed: 33152908
pii: S0753-3322(20)30910-0
doi: 10.1016/j.biopha.2020.110717
pii:
doi:
Substances chimiques
Plant Extracts
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110717Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.